Table 5. Comparison of AEs of any grade between the camrelizumab group and SoC group.

AEs	Camrelizumab group (n=28), n (%)	SoC group (n=13), n (%)	P value
Bone marrow suppression	22 (78.6)	10 (76.9)	0.906
Neurotoxicity	11 (39.3)	5 (38.5)	0.960
Nausea and vomiting	18 (64.3)	8 (61.5)	0.865
Diarrhea	10 (35.7)	5 (38.5)	0.741
Constipation	7 (25.0)	3 (23.1)	0.946
Stomatitis	9 (32.1)	8 (61.5)	0.013
Hand-foot syndrome	6 (21.4)	3 (23.1)	0.837
RCCEP	21 (75.0)	0	<0.001
Rash	4 (14.3)	1 (7.7)	0.562
Abnormal liver function	10 (35.7)	1 (7.7)	0.040
Hypothyroidism	7 (25.0)	0	0.039

AEs, adverse events; SoC, standard-of-care; RCCEP, reactive cutaneous capillary endothelial proliferation.